MDXH

+ Watchlist + Portfolio

MDxHealth SA

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.76
52-Week Range: $0.40 – $5.33
Market Cap: $68.70M
P/E (TTM): —
EPS (TTM): -0.71
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -9.83%
Gross Margin: 62.86%
Operating Margin: -18.74%
Profit Margin: -32.74%
Current Ratio: 1.15
Debt/Equity: —
Total Debt: $105.85M
Free Cash Flow: $-14.92M
Revenue Growth: 2.30%
Earnings Growth: —
Enterprise Value: $124.90M

MDXH Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$37.05M	$70.19M	$90.05M	$107.88M
Cost of Revenue	$17.84M	$26.26M	$34.91M	$38.24M
Gross Profit	$19.22M	$43.93M	$55.14M	$69.63M
Research & Development	$5.50M	$6.38M	$10.55M	$10.35M
Selling, General & Admin	$47.53M	$58.30M	$61.40M	$66.75M
Operating Expenses	$57.63M	$70.67M	$79.17M	$85.00M
Operating Income	-$38.41M	-$26.74M	-$24.03M	-$15.37M
EBITDA	-$36.50M	-$30.66M	-$22.02M	-$14.55M
Pretax Income	-$44.04M	-$43.10M	-$37.69M	-$35.38M
Income Tax	$0.00	$1.00K	$382.00K	-$1.86M
Net Income	-$44.04M	-$43.10M	-$38.07M	-$33.52M
Diluted EPS	-2.80	-1.66	-1.16	-0.67
Diluted Shares	15.73M	25.96M	49.50M	50.03M

MDXH Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$15.50M	$22.38M	$46.80M	$29.03M
Receivables	$9.51M	$11.27M	$14.53M	$14.73M
Inventory	$2.33M	$2.78M	$3.87M	$6.74M
Current Assets	$29.15M	$38.16M	$66.89M	$53.41M
Total Assets	$119.14M	$129.13M	$157.33M	$147.95M
Current Liabilities	$18.28M	$19.52M	$42.66M	$49.53M
Long-Term Debt	$34.91M	$35.56M	$50.97M	$76.20M
Total Debt	$39.79M	$41.27M	$60.06M	$86.60M
Total Liabilities	$109.82M	$121.92M	$142.49M	$160.05M
Retained Earnings	-$288.35M	-$331.45M	-$369.51M	-$403.03M
Shareholders' Equity	$9.31M	$7.21M	$14.84M	-$12.09M
Working Capital	$10.87M	$18.64M	$24.23M	$3.88M
Net Debt	$20.03M	$13.83M	$4.49M	$47.16M

MDXH Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$34.12M	-$21.50M	-$18.53M	-$2.19M
Capital Expenditure	-$4.16M	-$5.02M	-$2.16M	-$1.16M
Free Cash Flow	-$38.28M	-$26.52M	-$20.69M	-$3.35M
Depreciation & Amortisation	$4.91M	$6.86M	$8.04M	$9.21M
Stock-Based Compensation	$867.00K	$665.00K	$1.73M	$2.21M
Investing Cash Flow	-$29.04M	-$3.93M	-$1.64M	-$18.56M
Financing Cash Flow	$20.72M	$32.28M	$44.60M	$2.96M
Dividends Paid	$0.00	$0.00	$0.00	$0.00
Net Change in Cash	-$42.44M	$6.85M	$24.43M	-$17.78M

MDXH Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$24.29M	$26.61M	$27.43M	$29.55M	$27.39M
Cost of Revenue	$8.79M	$9.04M	$9.56M	$10.86M	$10.77M
Gross Profit	$15.50M	$17.57M	$17.88M	$18.69M	$16.61M
Research & Development	$2.50M	$2.57M	$2.01M	$3.28M	$2.13M
Selling, General & Admin	$15.66M	$16.16M	$18.05M	$16.88M	$20.52M
Operating Expenses	$20.09M	$19.48M	$20.52M	$24.91M	$23.92M
Operating Income	-$4.59M	-$1.92M	-$2.64M	-$6.22M	-$7.30M
EBITDA	-$1.65M	$770.00K	$114.00K	-$11.99M	$2.47M
Pretax Income	-$9.07M	-$7.79M	-$8.02M	-$10.50M	-$8.87M
Income Tax	$137.00K	-$416.00K	-$6.00K	-$1.57M	$0.00
Net Income	-$9.21M	-$7.37M	-$8.01M	-$8.93M	-$8.87M
Diluted EPS	-0.19	—	-0.16	-0.17	-0.17
Diluted Shares	48.47M	—	50.06M	52.52M	52.16M

MDXH Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$65.67M	$32.81M	$32.01M	$29.03M	$43.15M
Receivables	$15.54M	$15.71M	$18.24M	$14.73M	$14.26M
Inventory	$3.33M	$3.66M	$6.08M	$6.74M	$7.37M
Current Assets	$86.33M	$53.78M	$58.22M	$53.41M	$67.89M
Total Assets	$174.83M	$140.63M	$154.28M	$147.95M	$160.83M
Current Liabilities	$43.16M	$41.20M	$51.16M	$49.53M	$41.58M
Long-Term Debt	$75.37M	$75.66M	$75.92M	$76.20M	$95.95M
Total Debt	$83.98M	$84.01M	$87.91M	$86.60M	$105.88M
Total Liabilities	$168.87M	$141.52M	$162.54M	$160.05M	$181.06M
Retained Earnings	-$378.72M	-$386.10M	-$394.11M	-$403.03M	-$411.90M
Shareholders' Equity	$5.97M	-$883.00K	-$8.26M	-$12.09M	-$20.23M
Working Capital	$43.17M	$12.58M	$7.06M	$3.88M	$26.32M
Net Debt	$9.86M	$42.84M	$43.91M	$47.16M	$52.80M

MDXH Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$2.63M	-$1.60M	$1.66M	$378.00K	-$1.49M
Capital Expenditure	-$476.00K	-$364.00K	-$263.00K	-$54.00K	-$362.00K
Free Cash Flow	-$3.11M	-$1.96M	$1.40M	$324.00K	-$1.85M
Depreciation & Amortisation	$2.25M	$2.27M	$2.25M	$2.44M	$2.39M
Stock-Based Compensation	$391.00K	$680.00K	$447.00K	$693.00K	$562.00K
Investing Cash Flow	$13.00K	-$19.59M	-$775.00K	$1.79M	-$500.00K
Financing Cash Flow	$21.49M	-$11.69M	-$1.68M	-$5.15M	$16.11M
Dividends Paid	$0.00	$0.00	$0.00	$0.00	$0.00
Net Change in Cash	$18.87M	-$32.87M	-$795.00K	-$2.98M	$14.12M

Market Snapshot

About

MDxHealth SA is a commercial-stage precision diagnostics company focused on improving diagnosis and prognosis of urological cancers. The company offers molecular diagnostic tests including SelectMDx for prostate cancer risk assessment and ConfirmMDx for guiding repeat biopsy decisions in men with suspected prostate cancer.